Analyst consensus rating
Contineum Therapeutics Analyst Rating: Buy
Direct answer
Contineum Therapeutics's consensus rating is Buy.
7 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $22.14.
Forecast evidence checked October 17, 2026.
Get free Contineum Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $7.08
- Average price target
- $22.14
- High price target
- $30.00
- Low price target
- $14.00
- Low target gap
- +97.7%
- Target upside
- +212.8%
- High target gap
- +323.7%
- Target range width
- 226%
- Consensus rating
- Buy
- Analysts
- 7
- Evidence date
- October 17, 2026
- Valid through
- October 24, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Contineum Therapeutics?
Contineum Therapeutics has a verified Buy consensus. The same dataset has an average price target of $22.14.
How far are Contineum Therapeutics's low and high targets from the recorded price?
The low target implies +97.7%, while the high target implies +323.7%.
How many analysts are included in Contineum Therapeutics's consensus?
The verified consensus includes 7 analysts.
How is Contineum Therapeutics's target upside or downside calculated?
The average target of $22.14 is divided by the recorded price of $7.08, then one is subtracted to produce +212.8%. This does not guarantee a future return.
When was Contineum Therapeutics's analyst forecast verified?
The data was verified on 2026-10-17. The dataset is valid through 2026-10-24.